Bousquet, J; Gaudaño, EM; Palama Carlos, AG (1999). “A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis”. Allergy54 (6): 562–568. doi:10.1034/j.1398-9995.1999.00984.x. PMID10435469.
Van Cauwenberge, P; de Belder, T; Sys, L (2004). “A review of the second-generation antihistamine ebastine for the treatment of allergic disorders”. Exp Rew Pharmacother5 (8): 1807–13. doi:10.1517/14656566.5.8.1807. PMID15264995.
Antonijoan, R; García-Gea, C; Puntes, M (2007). “Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsules (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three period crossover study in healthy, nonatopic adults”. Clin Ther29 (5): 814–22. doi:10.1016/j.clinthera.2007.05.001. PMID17697901.
Ratner, P; Falqués, M; Chuecos, F (2005). “Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis”. Int Arch Allergy Immunol138 (4): 312–8. doi:10.1159/000088869. PMID16224195.
Antonijoan, RM; García-Gea, C; Puntes, M (2007). “A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults”. Clin Drug Invest27 (7): 453–61. doi:10.2165/00044011-200727070-00002. PMID17563125.
Gehanno, P; Bremard-Oury, C; Zeisser, P (1996). “Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults”. Annals of Allergy, Asthma and Immunol76 (6): 507–12. doi:10.1016/S1081-1206(10)63269-3. PMID8673684.
Bousquet, J; Gaudaño, EM; Palama Carlos, AG (1999). “A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis”. Allergy54 (6): 562–568. doi:10.1034/j.1398-9995.1999.00984.x. PMID10435469.
Van Cauwenberge, P; de Belder, T; Sys, L (2004). “A review of the second-generation antihistamine ebastine for the treatment of allergic disorders”. Exp Rew Pharmacother5 (8): 1807–13. doi:10.1517/14656566.5.8.1807. PMID15264995.
Antonijoan, R; García-Gea, C; Puntes, M (2007). “Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsules (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three period crossover study in healthy, nonatopic adults”. Clin Ther29 (5): 814–22. doi:10.1016/j.clinthera.2007.05.001. PMID17697901.
Ratner, P; Falqués, M; Chuecos, F (2005). “Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis”. Int Arch Allergy Immunol138 (4): 312–8. doi:10.1159/000088869. PMID16224195.
Antonijoan, RM; García-Gea, C; Puntes, M (2007). “A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults”. Clin Drug Invest27 (7): 453–61. doi:10.2165/00044011-200727070-00002. PMID17563125.
Gehanno, P; Bremard-Oury, C; Zeisser, P (1996). “Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults”. Annals of Allergy, Asthma and Immunol76 (6): 507–12. doi:10.1016/S1081-1206(10)63269-3. PMID8673684.